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Abstract We describe a case of a 62-year-old diabetic
woman with hepatocellular carcinoma due to chronic
hepatitis B virus infection. Two weeks after orthotopic
liver transplantation, endoscopy for massive upper gas-
trointestinal bleeding revealed a large necrotic area in
the gastric fundus. The patient underwent emergency
resection. Histopathologically, angioinvasive mold
infection compatible with mucormycosis was diagnosed
in a large area of necrosis, mimicking an atypically
localized gastric ulcer. Foreign bodies originating from
transarterial chemoembolization (TACE) performed 7
and 8 months earlier and 40 days before transplantation
were identified in the submucosal tissue. The patient
was treated with liposomal amphotericin B (LAB) for
5 weeks, followed by 7 weeks of posaconazole. Follow-
up biopsies after 1 and 5 months confirmed successful
treatment. Review of the radiological images of the
TACE procedure showed that some of the TACE
material had been diverted to the stomach via an
accessory gastric branch originating from the left
hepatic artery. TACE agents may be associated with
chronic, refractory gastroduodenal ulcers. We hypothe-
size that the ischemic lesion was first colonized with
presumed Mucorales mold and invasive growth was
promoted by the posttransplantation immunosuppres-
sion. Careful exploration of extrahepatic collaterals
during TACE may prevent this complication.
Introduction
The term ‘‘mucormycosis’’ denotes angioinvasive infection
by a few species of the fungal order of Mucorales. The
high-level taxonomy is currently evolving and the number
of recognized pathogenic species is increasing [1]. Most
isolates belong to the genera of Rhizopus, Mucor, Rhizo-
mucor, Lichtheimia, Apophysomyces, and Cunninghamella
[2]. The agents of mucormycosis are ubiquitous molds
found in decaying organic matter and soil. Infection results
from the inhalation of spores or inoculation through dis-
rupted skin or mucosa [3].
Mucorales can infect a more heterogeneous range of
human hosts and organs than other molds; yet, there are
specific risk factors: classically, people with poorly con-
trolled diabetes mellitus are prone to rhino-orbito-cerebral
disease, and skin breaches caused by trauma, surgery, or
burns may entail local soft tissue involvement. These forms
of the disease predominate in the developing world and in
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studies including older cases [2, 4]. In the last two decades,
the epidemiology has appeared to shift towards more
conventional risk factors, i.e., prolonged neutropenia due to
hematologic malignancies and immunosuppression for
solid organ transplantation (SOT), that more often entail
pulmonary involvement and a higher propensity for dis-
semination [2, 3, 5, 6]. Possible reasons for this change are
evolving treatment options, more widespread prophylactic/
preemptive use of antifungals non-effective for mucormy-
cosis, and a potential publication bias. In SOT patients, the
most frequent sites of initial infection are the lungs, fol-
lowed by rhino-cerebral, skin/soft tissue, and gastrointes-
tinal involvement [7].
Here, we report a case of presumed gastric mucormy-
cosis in an immunosuppressed patient with preexisting
chronic ischemic lesions due to aberrant transarterial
chemoembolization (TACE) material.
Case report
A 63-year-old patient of Southeast Asian descent was
referred for the treatment of a newly diagnosed hepato-
cellular carcinoma arising from chronic HBe antigen-neg-
ative hepatitis B virus infection. Comorbidities were an
insulin-dependent diabetes mellitus type 2, arterial hyper-
tension, and grade 2 chronic kidney disease. The initial
staging studies indicated widespread involvement of liver
segments II through IVb and VII. Tumor down-staging and
temporary control by TACE and scheduling for orthotopic
liver transplantation (OLT) was planned.
Shortly after the first TACE session, the patient suffered
from diffuse mucosal bleeding in the gastric corpus.
Endoscopically, tumor infiltration was suspected, but his-
tology revealed extensive non-neoplastic ischemic-ulcera-
tive alterations, presumably due to accidental TACE
spillover to an arterial branch supplying the stomach.
Indeed, a retrospective analysis of deeper tissue sections
revealed TACE material. Endoscopic controls confirmed
complete recovery of the gastric mucosa. TACE was
repeated after 1 and 6 months.
The patient received a deceased-donor organ 40 days
after TACE had been repeated due to tumor progression.
Mycophenolate mofetil 500 mg bid and a taper of high-
dose methylprednisolone was given for the induction of
immunosuppression, Tacrolimus 1 mg bid was added after
1 week. Gastroscopy for the placement of a nasoduodenal
tube again revealed non-bleeding corporal ulcerations
(Forrest III).
Two weeks after OLT, the patient incurred hemorrhagic
shock due to massive upper gastrointestinal bleeding. A
diffuse source around the previously mentioned lesions was
identified (Forrest Ib) but could not be stopped by
endoscopic adrenalin injections. The patient underwent
emergency ulcer resection (Fig. 1a).
Histopathological work-up showed a perforated ulcer
with invasively growing mold down to the muscular layer
of the stomach wall (Fig. 1b). The microscopic feature of
broad (about 10 lm), randomly, and sparsely septate
hyphae was consistent with mucormycosis (Fig. 1c).
Moreover, adjacent submucosal tissue revealed intravas-
cular amorphous, basophilic material arising from TACE
(Fig. 1d). Panfungal polymerase chain reaction (PCR)
subsequently performed from paraffin-embedded tissue
resulted negative. We consider these results as being false-
negative due to the minute amounts of material available
and reduced recovery of DNA from embedded tissues.
Fungal cultures could not be performed retrospectively
since no native tissue was left over. So, the diagnosis of
mucormycosis relies entirely on the morphology studies in
this case.
The pre-TACE celiac angiogram revealed a tiny left
hepatic branch running off to the stomach (Fig. 2a). In the
review of a reformatted coronal C-arm computed tomog-
raphy (CT) image, this accessory gastric branch could be
identified with a corresponding enhancement of a circum-
script area in the gastric fundus (Fig. 2b). This finding
corresponding to the secondary ulcer was appreciated only
retrospectively.
Thirty-six hours after ulcer resection, antifungal treat-
ment with liposomal amphotericin B (LAB) was started
(7.5 mg/kg/day). Treatment with mycophenolate was sus-
pended for 3 weeks and tacrolimus was withheld for
1 week, while immunosuppression with prednisolone was
maintained at a dose of 20 mg/day. An endoscopic control
after 5 weeks showed moderate chronic, focally active
gastritis without persisting mold infection. After 5 weeks
of full-dose LAB administration, antifungal treatment was
switched to posaconazole at a dose of 800 mg/day for
another 7 weeks. An additional biopsy 2 months later was
confirmative of successful antifungal treatment.
The postoperative course was complicated by repeated
bouts of bacterial septicemia, cytomegalovirus (CMV)
reactivation, and by the need for renal replacement therapy.
Acute on chronic renal failure in this patient was certainly
multifactorial, but may have been aggravated by prolonged
high-dose LAB administration.
Nine weeks after OLT, the patient could be sent to
rehabilitation and was later discharged home. However,
5 months after transplantation, she had to be readmitted
due to progressive chronic graft rejection and severe CMV
reactivation after the completion of secondary CMV pro-
phylaxis. The further course of disease was unfavorable;
6 weeks later, the patient died of liver failure and addi-
tional bacterial infectious complications while waiting for
retransplantation. No autopsy was performed.
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Fig. 1 Morphology of proximal gastric resection. a Gross specimen:
subtotal resection with mucosal hemorrhagic necrosis and perforation.
b Hematoxylin-eosin, 9100 magnification: necrotic submucosal
artery with invading hyphal structures (arrows) within partial mural
ischemic necrosis (inlay, hematoxylin-eosin, 925). c Grocott’s
methenamine silver stain (GMS), 9200: broad (10 lm), ribbon-like
hyphae with irregular septation and right-angle branching (arrows),
typical for Mucorales molds. d Hematoxylin-eosin staining, 950:
intravascular amorphous basophilic material (arrow) arising from
transarterial chemoembolization in submucosal tissue adjacent to the
necrotic center of the ulcer
Fig. 2 Radiologic studies before the last transarterial chemoemboli-
zation (TACE). a Celiac angiogram before the last TACE. The celiac
angiogram shows a large hypervascular hepatocellular carcinoma in
the left liver lobe (arrowheads). The tiny accessory left hepatic artery
branch (arrows) supplying the gastric fundus was overlooked, as non-
selective lobar chemoembolization with 100–300 lm doxorubicin-
eluting particles was performed. b Computed tomography (CT)
angiogram before the last TACE. The reformatted coronal C-arm CT
image performed before the delivery of the particles depicts the
hepatic tumor (arrowheads), the accessory gastric branch (small
arrows), and enhancement of a circumscript area in the gastric fundus
(large arrow)
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Discussion
Mucormycosis in SOT recipients is a rare event. According
to recent TRANSNET cohort data, the cumulative 1-year
incidence of invasive fungal infections is around 3 %.
Thereof, 2 % fall into the category of mucormycosis,
which equates to an overall 1-year cumulative incidence of
0.07 % [5, 8]. Interestingly, liver transplant recipients
appear to be at a higher risk (1-year incidence 0.16 %) and
suffered more often from disseminated disease than other
SOT recipients [5, 7]. This finding may indicate specific
defense defects in liver transplant recipients or simply
reflect a generally higher susceptibility for early fungal and
bacterial infection in these often severely sick patients
undergoing highly complex surgery.
In the most comprehensive case review of mucormy-
cosis [2], gastrointestinal disease figures with 7 % as a rare
form with exceptionally high mortality. The literature
before 1990 describes gastrointestinal mucormycosis pri-
marily as a disease of neonates, whereas more recently,
cases in patients with some underlying immunosuppression
and/or peptic ulcers are reported in increasing numbers [6,
9]. Pathogenicity is driven by early local tissue and angi-
oinvasion and subsequent tissue necrosis. Therefore,
hemorrhage or peritonitis are often the first symptoms [6].
In our patient, expeditious surgical intervention and radical
removal of the infested tissue was decisive. Indeed, the
contribution of subsequent antifungal treatment to infection
control remains unclear.
Our patient had several predisposing factors for invasive
gastrointestinal mucormycosis; apart from long-standing
(though well-controlled) diabetes mellitus and steroid-
based immunosuppression, she was malnourished and
suffered from renal failure. Yet, probably most crucial was
a preexisting ischemic damage of the gastric mucosa due to
aberrant TACE.
Non-target embolization or TACE spillover into adja-
cent arteries are well known to entail gastroduodenal
complications in up to 9 % of interventions [10]. Gastric
complications mostly present as gastritis or chronic,
refractory ulcers, which are rarely life-threatening [11]. No
cases of fungal superinfection are reported, but the patho-
genesis may be analogous to more common types of gastric
ulcers. Thomson et al. [9] observed a continuum of colo-
nization through infiltration to angioinvasion in cases of
gastric mucormycosis complicating peptic ulcers. It is
conceivable that, in our patient, colonization and possibly
infiltration of ischemic mucosal lesions treated with acid-
suppressive agents may have happened before transplan-
tation and progressed to invasive disease in the aftermath
of perioperative stress and posttransplant immunosuppres-
sion. This may explain its extraordinarily early occurrence
after transplantation.
Mucormycosis remains highly lethal despite multimodal
therapy. The overall mortality has declined from almost
100 % to approximately 40 % in the last 60 years,
remaining above 75 % in disseminated and gastrointestinal
disease and in patients after hematopoietic stem cell
transplantation [2, 7]. The cornerstones of successful
management are early diagnosis, surgical debridement,
improvement of the underlying conditions, and polyene-
based treatment. A treatment delay of as little as 6 days has
been shown to double mortality [12]. Thus, unspecific signs
and symptoms may often preclude timely action. Since
thrombosis of invaded vessels is a main trait of patho-
genesis and precludes the efficacy of antifungal drugs with
poor tissue penetration, thorough debridement of necrotic
tissue is crucial and was associated with survival in many
retrospective analyses [2, 7].
Besides posaconazole, only amphotericin B-based drugs
have a predictable activity against mucormycosis. Experi-
ments in mice [13] as well as, more recently, a series of
non-randomized clinical studies showed the superiority of
LAB and other lipid amphotericin B formulations over
amphotericin B deoxycholate [7, 14]. The advantages of
LAB are a better penetration into lipophilic tissues and
fewer nephrotoxic effects, which may allow for sufficient
dosing. Since certain agents of mucormycosis such as
Cunninghamella and Rhizopus spp. display relative in vitro
tolerance to the fungicidal effects of amphotericin B [15],
higher dosing appears appealing. However, a randomized
trial in patients with invasive mold infections (mostly
Aspergillus spp.) comparing a high loading dose regimen
of LAB (10 mg/kg) with lower dosing (3 mg/kg) did not
show any additional benefit for higher dosing but higher
rates of nephrotoxicity [16]. Whether the agents of
mucormycosis behave clinically different from Aspergillus
spp. in this respect remains to be determined. Meanwhile,
most experts recommend LAB doses of at least 5 mg/kg
for the treatment of mucormycosis, although few formal
recommendations exist [17, 18].
Likewise, the question regarding a reasoned use of
combination treatment remains unsettled. A matter of
debate is the combination of polyenes with echinocandins,
which, as monotherapeutics, have virtually no impact on
Mucorales growth in vitro. Experiments in ketoacidotic
mice as well as small retrospective studies suggest a syn-
ergy of caspofungin and LAB [13, 19]. Due to obvious
obstacles to performing sufficiently powered randomized
studies on this rare and highly heterogeneous disease,
combination therapy might eventually become the de facto
standard of care on the grounds of scanty evidence.
In conclusion, this report is the first—to our knowl-
edge—to present a case of invasive infection of a preex-
isting gastric mucosal lesion due to aberrant TACE with
mucormycosis. It demonstrates that such ischemic lesions
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may be prone to fungal infectious complications in the
setting of posttransplant stress and immunosuppression. It
underscores the importance of careful exploration of ana-
tomical variant collaterals before TACE and thorough
histologic work-up in unusual cases of upper gastrointes-
tinal bleeding.
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